Literature DB >> 23857095

Castleman's disease accompanied by hypolipidemic cerebral hemorrhage and nephrosclerosis.

Aya Imafuku1, Tatsuya Suwabe, Eiko Hasegawa, Koki Mise, Keiichi Sumida, Rikako Hiramatsu, Masayuki Yamanouchi, Noriko Hayami, Junichi Hoshino, Naoki Sawa, Kenichi Oohashi, Takashi Fujii, Minoru Okubo, Kenmei Takaichi, Tatsuhide Oga, Yoshifumi Ubara.   

Abstract

A 56-year-old Japanese man developed a cerebral hemorrhage and was diagnosed with plasma cell-type multicentric Castleman's disease (MCD) based on the findings of an inguinal lymph node biopsy in addition to clinical findings, including hypergammaglobulinemia, anemia and elevation of the levels of CRP and serum IL-6. Although a renal biopsy showed nephrosclerosis, the levels of serum lipids and apolipoprotein were low. Following the initiation of treatment with anti-interleukin-6 receptor antibodies, the hypergammaglobulinemia, anemia, CRP level and serum lipid profile improved. However, inflammation due to overproduction of IL-6 persisted, and atherosclerotic vascular events occurred as critical complications, even though the serum levels of lipids were very low.

Entities:  

Mesh:

Year:  2013        PMID: 23857095     DOI: 10.2169/internalmedicine.52.0271

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report.

Authors:  Shoko Noda-Narita; Keiichi Sumida; Akinari Sekine; Junichi Hoshino; Koki Mise; Tatsuya Suwabe; Noriko Hayami; Masayuki Yamanouchi; Toshiharu Ueno; Hiroki Mizuno; Masahiro Kawada; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi; Kenichi Ohashi; Takeshi Fujii; Yoshifumi Ubara
Journal:  CEN Case Rep       Date:  2018-02-21

2.  Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease.

Authors:  Yushiro Endo; Tomohiro Koga; Yoshihumi Ubara; Remi Sumiyoshi; Kaori Furukawa; Atsushi Kawakami
Journal:  Clin Exp Immunol       Date:  2021-07-26       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.